• For the frequentist GLIMMIX approach, the impact on the results based on the estimation method and degrees of freedom calculation method was also assessed:
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The authors wish to thank Adele Monroe and Candy Webster for editorial and design assistance in the preparation of this poster and would like to thank Christina Radder for her programming assistance. • Indirect comparison meta-analysis techniques continue to develop, and software now exists to model networks of randomized clinical trials (RCTs) using Bayesian or frequentist approaches with trial effects treated as fi xed or random. The anchored indirect [treatment] comparison (AIC) method, which is not model based, is also suitable for making these treatment comparisons.
CONTACT INFORMATION
• Many meta-analyses are performed with a very limited number of studies. In a review of thousands of metaanalyses, Davey et al. (2011) 1 reported that over one-third included the minimum requirement of two studies only, and just under three-quarters contained fi ve or fewer studies. However, practical issues emerge, particularly when the network comprises a limited number of studies.
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• Our goal was to investigate the performance and interpretation of different indirect comparison meta-analysis methods when few studies are available. Of special interest is the situation in which a star network contains only one trial for each given treatment comparison.
METHODS
• A star network based on two trials anchored by placebo was created for a binary endpoint ( Figure 1 ).
• Using this network, the odds ratio from Trial #1 (Drug A vs. placebo) can be compared with the odds ratio from Trial #2 (Drug B vs. placebo) to create an indirect comparison of Drug A versus Drug B.
• Sample data were created for nine different scenarios in the network by varying sample size and placebo response (see Table 1 ). a A random effect for trial was not estimable and instead, a fi xed effect for trial was used.
• For each scenario, indirect-comparison meta-analyses examining the odds ratio of drug A versus drug B were produced using the following three methods: -Non-model based method 1. AIC method 5, 6 : The AIC method is equivalent to a generalized linear model with a logit link in which treatment and trial are fi xed effects.
-Model-based methods: For a binary endpoint that follows a binomial distribution (logit link) with a fi xed effect for treatment and a random effect for trial. Note that the Bayesian approach and the frequentist approach both use the same fundamental statistical model, which is a generalized linear mixed model (GLMM). The primary difference is in the approach to parameter estimation.
2. Bayesian approach using WinBUGS software (Bayesian inference using Gibbs sampling): Noninformative prior distributions used with 10,000 burn-in simulations followed by 10,000 simulations for estimation; model was thinned by a factor of 5.
3. Frequentist approach using PROC GLIMMIX in SAS software (version 9.3, SAS Institute, Cary, North Carolina, USA): A no-intercept model with logit link, estimation method=RSPL, and degrees of freedom method=NONE. Note that if a random effect for trial was not estimable in a model, then it was treated as a fi xed effect instead.
• The odds ratio estimates for the indirect comparisons are generally not expected to be equal in the AIC and modelbased methods, since the AIC method assumes a fi xed effect for trial and the model-based methods specify a random effect for trial.
RESULTS
• Estimated odds ratios from the indirect comparison (A vs. B) were examined to identify patterns of performance of the three methods across the nine scenarios (see Table 2 and Figure 2a-2c ).
General Observations
Scenarios 1, 4, 7: Placebo Response Rates Were the Same across the Two Studies
• The GLIMMIX approach could not estimate a random effect for trial, and it was necessary to run a model with a fi xed effect for trial. As expected, GLIMMIX and AIC results were identical since the AIC method is equivalent to the GLIMMIX approach.
• The WinBUGS model (with random effect for trial) produced odds ratios very similar to those produced by the GLIMMIX and AIC methods.
• The confi dence intervals do not indicate a signifi cant difference across the methods. • The GLIMMIX approach produced consistently higher odds ratio estimates than the WinBUGS approach, which in turn produced consistently higher odds ratio estimates than the AIC method. Again, the confi dence intervals overlapped between all three methods, indicating that they are not statistically different.
• Before conducting the analyses, we expected that the GLIMMIX and WinBUGS approaches would produce similar odds ratio estimates because they were based on the same fundamental model. However, slight differences in results were noted between the two approaches:
-When the difference between the placebo response rates was "small" (45% vs. 37%), the odds ratio from the GLIMMIX approach demonstrated the greatest difference from the odds ratio produced by the WinBUGS approach (e.g., scenario 2: WinBUGS OR=1.87, GLIMMIX OR=2.24), compared with when the difference between the placebo response rates was "large" (45% vs 32%) (e.g., scenario 3: WinBUGS OR=1.52, GLIMMIX OR=1.63). 
